01647nas a2200337   4500000000100000008004100001260001600042653001200058653002100070653001900091653001200110653002700122653003700149653003900186653002300225653000900248653002700257653000900284653001700293653002500310653002200335100001200357700002000369700002400389700001600413245008700429300001000516490000800526520076100534022001401295       2004                            d  c2004 Mar 0510aAnimals10aBrain Infarction10aBrain Ischemia10aDapsone10aDisease Models, Animal10aDose-Response Relationship, Drug10aInfarction, Middle Cerebral Artery10aLeprostatic Agents10aMale10aNeuroprotective Agents10aRats10aRats, Wistar10aRecovery of Function10aTreatment Outcome1 aRíos C1 aNader-Kawachi J1 aRodriguez-Payán AJ1 aNava-Ruiz C00aNeuroprotective effect of dapsone in an occlusive model of focal ischemia in rats.  a212-50 v9993 a<p>Dapsone (4,4'-diaminodiphenylsulfone) is employed in the chemotherapy against leprosy. Dapsone also prevents neuronal damage induced by glutamate agonists. As glutamate excitotoxicity is implicated in the damage after ischemia, we tested the ability of dapsone to prevent ischemic injury in a model of permanent middle cerebral artery (MCA) occlusion in rats. Either dapsone (9.375 or 12.5 mg/kg doses) or vehicle were i.p. administered 30 min after occlusion. Rats from the control group showed a permanent neurological deficit after occlusion, while dapsone-treated groups improved significantly. Dapsone-treated animals showed a reduction of 93% (9.375 mg/kg dose) and 92% (12.5 mg/kg dose) in the infarction volume as compared to control values.</p>  a0006-8993